—OMC
— • —
$74.77
P/E
151.20
PEG
—
FCF Yield
—
Rev Growth YoY
+1009.0% YoY
Gross Margin
2679.0%
Health Score
3/10
D/E Ratio
0.76
Confidence
LOW
Business Snapshot
The ticker and exchange data are absent from this payload, which severely limits company-specific context. Based on available financial ratios — a Price/Sales of 1.34x, a Price/Book of 2.11x, and an EV/EBITDA of 9.12x — this appears to be a revenue-stage company trading at $74.77 per share. Without market capitalisation data, a definitive cap-tier classification cannot be made, though the combination of explosive reported revenue growth and deeply negative net margins is consistent with a small- to mid-cap growth or turnaround-stage business.
Financial Health
**Score: 3/10** The financial health picture is strained across multiple dimensions. The net margin stands at -32.0%, meaning the company loses roughly 32 cents on every dollar of revenue — a significant drag on sustainability...
Risk Assessment
- **VALUATION: P/E of 151.2x is approximately 6x the sector average of 25x, with no DCF support available and negative free cash flow.** - **PROFITABILITY: Net margin of -32.0% combined with an earnings growth rate of -9,337.0% signals rapidly worsening losses even as revenue surges.** - **LIQUIDITY: Current ratio of 0.93x falls below the 1.0x minimum safety threshold, raising short-term solvency concerns.** - **RETURN ON CAPITAL: Return on equity of -85.0% indicates significant destruction of shareholder value in the current period.** - **TECHNICALS: A confirmed death cross (50-day MA crossing below 200-day MA) and a bearish MACD signal suggest negative price momentum with no moving average support visible.** ---...